These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 34325888)

  • 21. Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure.
    Hundertmark MJ; Agbaje OF; Coleman R; George JT; Grempler R; Holman RR; Lamlum H; Lee J; Milton JE; Niessen HG; Rider O; Rodgers CT; Valkovič L; Wicks E; Mahmod M; Neubauer S
    ESC Heart Fail; 2021 Aug; 8(4):2580-2590. PubMed ID: 33960149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo-controlled study.
    Thiele K; Rau M; Hartmann NK; Möllmann J; Jankowski J; Böhm M; Keszei AP; Marx N; Lehrke M
    Diabetes Obes Metab; 2021 Dec; 23(12):2814-2818. PubMed ID: 34378852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial.
    Nassif ME; Qintar M; Windsor SL; Jermyn R; Shavelle DM; Tang F; Lamba S; Bhatt K; Brush J; Civitello A; Gordon R; Jonsson O; Lampert B; Pelzel J; Kosiborod MN
    Circulation; 2021 Apr; 143(17):1673-1686. PubMed ID: 33550815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure.
    Abraham WT; Ponikowski P; Brueckmann M; Zeller C; Macesic H; Peil B; Brun M; Ustyugova A; Jamal W; Salsali A; Lindenfeld J; Anker SD;
    Eur J Heart Fail; 2019 Jul; 21(7):932-942. PubMed ID: 31218819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial.
    Packer M; Anker SD; Butler J; Filippatos G; Ferreira JP; Pocock SJ; Sattar N; Brueckmann M; Jamal W; Cotton D; Iwata T; Zannad F;
    J Am Coll Cardiol; 2021 Mar; 77(11):1381-1392. PubMed ID: 33736819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence.
    Aguilar-Gallardo JS; Correa A; Contreras JP
    Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):311-321. PubMed ID: 34264341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sodium glucose co-transporter 2 inhibition with empagliflozin on metabolic, cardiac and renal outcomes in recent cardiac transplant recipients (EMPA-HTx): protocol for a randomised controlled trial.
    Raven LM; Muir CA; Kessler Iglesias C; Bart NK; Muthiah K; Kotlyar E; Macdonald P; Hayward CS; Jabbour A; Greenfield JR
    BMJ Open; 2023 Mar; 13(3):e069641. PubMed ID: 36990488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action.
    Packer M; Anker SD; Butler J; Filippatos G; Zannad F
    JAMA Cardiol; 2017 Sep; 2(9):1025-1029. PubMed ID: 28768320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Empagliflozin on Blood Volume Redistribution in Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the Empire HF Randomized Clinical Trial.
    Omar M; Jensen J; Burkhoff D; Frederiksen PH; Kistorp C; Videbæk L; Poulsen MK; Gustafsson F; Køber L; Borlaug BA; Schou M; Møller JE
    Circ Heart Fail; 2022 Mar; 15(3):e009156. PubMed ID: 34743533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of empagliflozin treatment on cardiac function and structure in patients with type 2 diabetes: a cardiac magnetic resonance study.
    Cohen ND; Gutman SJ; Briganti EM; Taylor AJ
    Intern Med J; 2019 Aug; 49(8):1006-1010. PubMed ID: 30784160
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
    Kato ET; Silverman MG; Mosenzon O; Zelniker TA; Cahn A; Furtado RHM; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Bonaca MP; Ruff CT; Desai AS; Goto S; Johansson PA; Gause-Nilsson I; Johanson P; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
    Circulation; 2019 May; 139(22):2528-2536. PubMed ID: 30882238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial.
    Shimizu W; Kubota Y; Hoshika Y; Mozawa K; Tara S; Tokita Y; Yodogawa K; Iwasaki YK; Yamamoto T; Takano H; Tsukada Y; Asai K; Miyamoto M; Miyauchi Y; Kodani E; Ishikawa M; Maruyama M; Ogano M; Tanabe J;
    Cardiovasc Diabetol; 2020 Sep; 19(1):148. PubMed ID: 32977831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease.
    Mason T; Coelho-Filho OR; Verma S; Chowdhury B; Zuo F; Quan A; Thorpe KE; Bonneau C; Teoh H; Gilbert RE; Leiter LA; Jüni P; Zinman B; Jerosch-Herold M; Mazer CD; Yan AT; Connelly KA
    JACC Cardiovasc Imaging; 2021 Jun; 14(6):1164-1173. PubMed ID: 33454272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
    Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
    Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction.
    Yurista SR; Silljé HHW; Oberdorf-Maass SU; Schouten EM; Pavez Giani MG; Hillebrands JL; van Goor H; van Veldhuisen DJ; de Boer RA; Westenbrink BD
    Eur J Heart Fail; 2019 Jul; 21(7):862-873. PubMed ID: 31033127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
    Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
    Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients.
    Nakagawa Y; Kuwahara K
    J Cardiol; 2020 Aug; 76(2):123-131. PubMed ID: 32340780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sodium-glucose co-transporter-2 inhibitors eligibility in patients with heart failure with reduced ejection fraction.
    Monzo L; Ferrari I; Cicogna F; Tota C; Calò L
    Int J Cardiol; 2021 Oct; 341():56-59. PubMed ID: 34454968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial.
    Jensen J; Omar M; Kistorp C; Poulsen MK; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Faber J; Fosbøl EL; Bruun NE; Brønd JC; Forman JL; Videbæk L; Møller JE; Schou M
    Am Heart J; 2020 Oct; 228():47-56. PubMed ID: 32798787
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial.
    Bosch A; Ott C; Jung S; Striepe K; Karg MV; Kannenkeril D; Dienemann T; Schmieder RE
    Cardiovasc Diabetol; 2019 Mar; 18(1):44. PubMed ID: 30922297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.